坦索罗辛与索利那新联合治疗前列腺增生的疗效观察

Effectiveness of combined therapy with tansuoluoxin and solifenacin for patients with be- nign prostatic hyperplasia

目的观察坦索罗辛与索利那新两药联合治疗良性前列腺增生的临床疗效。方法选择52例因患良性前列腺增生来我院治疗的患者，所有患者均有排尿困难，随机选择28例作为观察组，给予坦索罗辛、索利那新联合治疗；余24例作为对照组，给予坦索罗辛单药治疗。以10周为一疗程，一疗程结束后比较两组在治疗前后各项测定指标差异，同时比较治疗后两组各项测定指标的差异结果用药10周后，国际前列腺症状评分、储尿期刺激症状评分、残余尿量、24h排尿次数、尿失禁次数及夜尿两组较治疗前均有明显下降（P〈0．05），两组最大尿流率和24h平均尿量较治疗前也有较明显的上升（P〈0．05）；治疗结束后，两组结果比较显示，观察组国际前列腺症状评分、储尿期刺激症状评分、24h尿失禁次数和夜尿次数与对照组比较有明显改善，两组差异具有统计学意义（P〈0．05）。结论坦索罗辛和索利那新两药联合治疗良性前列腺增生，可明显改善患者尿流动力学障碍，降低梗阻，显著改善患者整体生活质量。

Objectives To evaluate the clinical efficacy of combined therapy with tansuoluoxin and solifenacin for patients with benign prostatic hypcrplasia. Methods 52 patients with benign prostatic hyperplasia without serious obstructive symptom were randomly assigned to two groups. 28 patients are observation group, treated with tansuoluoxin and solifenacin. 24 patients are contorl group, treated with tansuoluoxin only; after ten weeks of treatment, compere the before and after difference of the measured indicators. And the difference in determination of indicators after treatment. Results Ten weeks after treatment, the IPSS, score on the urinary storage phase symptoms, residual urine volume, number of micturation per 24h, number of incontinence per 24h and number of enuresis nocturna significantly decreased in tansuoluoxin group （ P 〈 0.05 ） , while maximum urinary flow rate and mean voi- ding volume significantly increased（ P 〈 0.05 ）. There were significant differences in IPSS, score on the urinary storage phase symptoms, number of incontinence and number of enuresis nocturna between two groups after treatment（ P 〈 0. 05）. Conclusions Transurethral ureteroscopic treatment of hemospermia is an effective way, there are less postoperative complications, it has a good clinical value.